» Articles » PMID: 38505563

Transcriptome Analysis Reveals Distinct Patterns Between the Invasive and Noninvasive Pituitary Neuroendocrine Tumors

Abstract

Although most pituitary neuroendocrine tumors (PitNETs)/pituitary adenomas remain intrasellar, a significant proportion of tumors show parasellar invasive growth and 6% to 8% infiltrate the bone structures, thus affecting the prognosis. There is an unmet need to identify novel markers that can predict the parasellar growth of PitNETs. Furthermore, mechanisms that regulate bone invasiveness of PitNETs and factors related to tumor vascularization are largely unknown. We used genome-wide mRNA analysis in a cohort of 77 patients with PitNETs of different types to explore the differences in gene expression patterns between invasive and noninvasive tumors with respect to the parasellar growth and regarding the rare phenomenon of bone invasiveness. Additionally, we studied the genes correlated to the contrast enhancement quotient, a novel radiological parameter of tumor vascularization. Most of the genes differentially expressed related to the parasellar growth were genes involved in tumor invasiveness. Differentially expressed genes associated with bone invasiveness are involved in NF-κB pathway and antitumoral immune response. Lack of clear clustering regarding the parasellar and bone invasiveness may be explained by the influence of the cell lineage-related genes in this heterogeneous cohort of PitNETs. Our transcriptomics analysis revealed differences in the molecular fingerprints between invasive, including bone invasive, and noninvasive PitNETs, although without clear clustering. The contrast enhancement quotient emerged as a radiological parameter of tumor vascularization, correlating with several angiogenesis-related genes. Several of the top genes related to the PitNET invasiveness and vascularization have potential prognostic and therapeutic application requiring further research.

Citing Articles

Comprehensive transcriptomic analysis identifies three distinct subtypes of pituitary adenomas: insights into tumor behavior, prognosis, and stem cell characteristics.

Peng J, Yuan L, Kang P, Jin S, Ma S, Zhou W J Transl Med. 2024; 22(1):892.

PMID: 39363281 PMC: 11448088. DOI: 10.1186/s12967-024-05702-w.


scRNA sequencing technology for PitNET studies.

Asaad W, Utkina M, Shcherbakova A, Popov S, Melnichenko G, Mokrysheva N Front Endocrinol (Lausanne). 2024; 15:1414223.

PMID: 39114291 PMC: 11303145. DOI: 10.3389/fendo.2024.1414223.


Transcriptome Analysis Reveals Distinct Patterns Between the Invasive and Noninvasive Pituitary Neuroendocrine Tumors.

Jotanovic J, Tebani A, Hekmati N, Sivertsson A, Lindskog C, Uhlen M J Endocr Soc. 2024; 8(5):bvae040.

PMID: 38505563 PMC: 10949357. DOI: 10.1210/jendso/bvae040.

References
1.
Silveira W, Palma P, Sicchieri R, Villacis R, Mandarano L, Oliveira T . Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype. Sci Rep. 2017; 7(1):2851. PMC: 5460106. DOI: 10.1038/s41598-017-02761-6. View

2.
Silva-Junior R, Bueno A, Martins C, Coelli-Lacchini F, Ozaki J, Almeida-E-Silva D . Integrating Methylome and Transcriptome Signatures Expands the Molecular Classification of the Pituitary Tumors. J Clin Endocrinol Metab. 2022; 108(6):1452-1463. DOI: 10.1210/clinem/dgac703. View

3.
Elston M, Gill A, Conaglen J, Clarkson A, Shaw J, Law A . Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology. 2007; 149(3):1235-42. DOI: 10.1210/en.2007-0542. View

4.
Goel A, Nadkarni T, Muzumdar D, Desai K, Phalke U, Sharma P . Giant pituitary tumors: a study based on surgical treatment of 118 cases. Surg Neurol. 2004; 61(5):436-45. DOI: 10.1016/j.surneu.2003.08.036. View

5.
Knosp E, Steiner E, Kitz K, Matula C . Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993; 33(4):610-7; discussion 617-8. DOI: 10.1227/00006123-199310000-00008. View